Shanghai Hengrui Pharmaceutical Co., Ltd.
Works in Cardiovascular · GI & liver · Hematology · Immunology · Metabolic & endocrine · Neurology · Oncology · Psychiatry · Respiratory
Shanghai Hengrui Pharmaceutical Co., Ltd. is a clinical trial sponsor. It has 26 active clinical trials with 5,741 planned participants, across 9 therapeutic areas. Since 2021 it has completed 20 trials and stopped 4 early.
Trial track record · since 2021
Pipeline · 26 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Shanghai Hengrui Pharmaceutical Co., Ltd
Shanghai Hengrui Pharmaceutical Co., Ltd is lead sponsor of 26 active clinical trials on ClinicalTrials.gov, with 5,741 planned participants, in Cardiovascular, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 20 trials and stopped 4 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Shanghai Hengrui Pharmaceutical Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-15.
Approve Suite is not affiliated with Shanghai Hengrui Pharmaceutical Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.